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Conclusion: In TTR amyloidosis, NTproBNP and troponin T are associ-
ated with LV impairment measured by echocardiography suggesting that
NTproBNP could be useful in FAP carriers to start echocardiographic follow-
up whereas troponin would identify patients with severe cardiac disease.
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Background: Transthyretin familial amyloid polyneuropathy (TTR-FAP)
is an autosomal dominant disease characterized by extracellular amyloid
deposition in the nerves and heart. Orthotopic liver transplant (OLT) is recom-
mended to remove the source of mutated TTR and stop amyloid deposition.
However, progressive cardiomyopathy due to continuing amyloidosis has been
described following OLT in patients with non-V30M mutations. Tafamidis
prevents dissociation of TTR into monomers and formation of amyloid.
Objectives: To evaluate cardiac safety and tolerability of tafamidis in
patients with non-V30M TTR-FAP.
Methods: Patients (N=21) with TTR-FAP due to non-V30M TTR muta-
tions and no OLT history were studied in a phase 2 open-label trial. Cardiac
assessments included ECG, 24-hour Holter monitoring, echocardiogram,
and cardiac biomarkers (troponin I and NT-pro-BNP) at baseline and 6 and
12 months.
Results: Of the 21 patients enrolled, mean (SD) age, LVEF, troponin I,
and NT-pro-BNP at baseline were 63.1 (9.86) years, 60.3 (9.96)%,
0.023(0.04) ng/mL, and 1248.9 (1529.4) pg/mL, respectively. Nine patients
had a history of cardiac events. Six of these 9 experienced peripheral edema
or dyspnea related to heart failure while on treatment, and 3 patients were hos-
pitalized for other cardiovascular events (AV block, coronary stenosis, TIA).
Eighteen patients completed the study, with no significant changes in troponin
I, LVEF, or cardiac remodeling. NT-pro-BNP, while elevated at baseline,
remained stable with no clinically relevant changes. The pattern of Holter
monitoring abnormalities was similar at baseline and while on treatment (eg,
atrial tachycardia, 52.4% [11/21] vs 44.4% [4/9]). The percentage of patients
with normal heart rate variability (HRV) increased from 21% (4/19) at base-
line to 42% (8/19) at month 12.
Discussion: This study showed no deleterious effects of tafamidis on car-
diac function among a cohort of treated TTR-FAP patients. The number of
patients with normal HRV improved.
Conclusion: Tafamidis was safe and well tolerated in patients with non-
V30M TTR-FAP.
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Pupose: Diastolic Left ventricular (LV) dysfunction is a common finding
in sickle cell disease. Furthermore, left atrial (LA) size usually reflects left
ventricular filling pressures.
The aim of our study was to determine if LA size is an expression of left
ventricular filling pressures or reflects remodelling associated with anemia
and/or haemolysis in sickle cell disease.
Methods: We evaluated 127 patients with sickle cell disease in stable
condition (mean age 28,6±8,5 years, 83 women) and 38 age and sex-matched
healthy controls. LA size was measured with Simpson’s method in apical 4-
chamber view. LV filling pressures were assessed using ratio between pulsed
Doppler peak E velocity and peak Ea velocity obtained with tissue Doppler
imaging of the lateral annulus (E/Ea ratio). Clinical and biologic data were
collected from clinical records.
Results: Compared with the normal group, patients with sickle cell disease
had a LA volume and E/Ea ratio significatively increased (48,4±11,2 ml/m²
and 5,9±1,7 ; 30,5±7,6 ml/m² and 4,5±1, respectively, p<0.0001).
In multivariate analysis, LA enlargement in patients is only influenced by
age and haematological parameters (haemoglobin and reticulocyte levels).
No correlation was found between LA volume and E/Ea ratio (figure). 
Conclusion: Subjects with sickle cell disease have LA enlargement. However,
in this population, LA dilatation is not an index of left ventricular filling pressures.
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Background: Several arrhythmias were reported in myotonic dystrophy
(MD). The most frequent would be conduction disturbances and ventricular
arrhythmias. The purpose of the study was to evaluate the prevalence of atrial
flutter and fibrillation (AF) in MD and the consequences.
Methods: 157 patients, 80 men and 77 women, aged from 16 to 70 years,
mean age 41±14 years, at the inclusion, were consecutively recruited for a
type 1 MD. Patients were asymptomatic at the inclusion, except 4. Patients
were followed during 4.5±3.5 years. ECG, left ventricular ejection fraction
(LVEF) determination at echocardiography, Holter monitoring, signal-aver-
aged ECG were obtained and repeated.
Results: 24 patients presented sustained (> 1 hour) AF or atrial flutter
(n=8). The prevalence was 15%. Among these patients 2 presented a 1/1 atrial
flutter associated with syncope. In one of them, 16 years old, cardiac defibril-
lator was implanted for a diagnosis of ventricular tachycardia, but the real diag-
nostis was made after inappropriate shocks. Atrial flutter ablation was performed
in 4 patients but 3 of them developed AF. During follow-up, 21 patients died
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